

**29 April 2009**

## **VitroGro® produces 32% healing of chronic diabetic ulcer in 6 weeks - second patient in Canadian trial**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced that patient recruitment into the clinical trial of VitroGro® in Toronto, Canada is continuing on schedule, with excellent results.

Clinical data reported for the second patient show a 32% reduction in the size of the chronic diabetic ulcer on the patient's left heel in 6 weeks, despite significant complicating clinical factors including severe diabetes, kidney failure requiring dialysis and continued heavy growth of bacteria in the ulcer despite antimicrobial therapy.

The reduction in this diabetic ulcer by almost one third in 6 weeks is exceptional since this patient has had his right lower leg amputated and uses a right lower leg prosthesis (artificial leg) that prevents him from effectively unloading his left heel ulcer. Unloading and weight redistribution is usually essential for the healing of chronic wounds.

The CEO of Tissue Therapies, Dr Steven Mercer said, "In many ways the results from this patient are even more outstanding than the first patient where a 29% reduction was achieved in 6 weeks."

"Healing 32 % of a chronic diabetic ulcer in 6 weeks would be an excellent result in any patient, but given the clinical complications this man suffers including an artificial right lower leg preventing unloading of his left heel ulcer, this really is an exceptional outcome."

He also said, "I am also delighted to say that the first patient has continued to heal his chronic diabetic ulcer up to week 12 of the study despite being a diabetic with high blood pressure and continuing to smoke."



- 60 year old male, diabetic
- Renal dialysis since kidney failure in early 2008
- Right below knee amputation due to diabetes & uses a right lower leg prosthesis
- Diabetic ulcer on left heel
- Right artificial leg increases pressure on left foot, making treatment of left heel ulcer more difficult
- 32% reduction in diabetic ulcer area in 6 weeks with VitroGro® treatment despite heavy presence of bacteria
- Rapid healing of ulcer from the edges and from the base with healthy new tissue in floor of the ulcer
- No adverse reactions to VitroGro®

This clinical trial is being conducted at two wound care centres run by internationally respected wound healing clinician Professor Gary Sibbald in Toronto, Canada. The protocol is designed to test VitroGro® for the treatment of diabetic, venous and pressure ulcers and completion of this human trial is expected by 30 June 2009.

Further information: Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938  
  
Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

### **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information:** [www.tissuetherapies.com](http://www.tissuetherapies.com)